CRX.L Regulatory News (CRX)

6 Jun 2007 10:30

Cyprotex PLC06 June 2007 6th June 2007 Cyprotex PLC (the "Company" or "Cyprotex") Annual General Meeting "Cyprotex continues to build momentum and reputation within its globalpharmaceutical client base. Such endorsement underlines the Group's position atthe technological forefront of ADME/Tox* screening, whilst recognising theopportunity of the international market place it addresses. The extraordinary general meeting that was called earlier this year by a groupof 'Requisitionists' intent on unseating the present management wasoverwhelmingly defeated. Despite causing a very unnecessary and costlydiversion of resources for your company, the Board took rapid action to ensurethat progress during the first six months of 2007 was not derailed. At this time, Cyprotex appears to be ending the first half on a strong note.Moreover, the continued expansion of its customer base and anticipation ofdeepening collaboration opportunities within the 'Top Ten' global giants bodesvery well for the second half." * ADME/Tox - Absorption, Distribution, Metabolism, Excretion/Toxicity For further information: Cyprotex PLCRobert Morrison Atwater, Chairman and Chief Executive OfficerTel: +44 (0)1625 505 100ir@cyprotex.comwww.cyprotex.com Code Securities LimitedCharles Walker, Corporate FinanceTel: +44 (0)20 7776 1200cic@codesecurities.comwww.codesecurities.com Media Enquires:WMC CommunicationsAlex GloverTel: +44 (0) 20 7930 9030alex.glover@wmccommunications.com This information is provided by RNS The company news service from the London Stock Exchange